Special Instructions
State patient's age and sex on the request form.
Expected Turnaround Time
Within 1 day
Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary.
Related Documents
For more information, please view the literature below.
Specimen Requirements
Specimen
Serum (preferred) or plasma and random urine
Volume
3 mL serum or plasma and 10 mL urine
Minimum Volume
1 mL serum or plasma and 2 mL urine
Container
Red-top tube, gel-barrier tube, or green-top (lithium heparin) tube. Do not use oxalate, EDTA, or citrate plasma and plastic urine container.
Collection
Separate serum or plasma from cells within 45 minutes of collection. Lipid panels are best avoided for up to three months following acute myocardial infarction, although cholesterol can be measured in the first 24 hours.
Collect random urine without preservatives. pH must be 4 to 8.
Storage Instructions
Maintain specimens at room temperature.
Stability Requirements
Temperature | Period |
|---|---|
Room temperature | 3 days |
Refrigerated | 14 days |
Frozen | 14 days |
Freeze/thaw cycles | Stable x2 |
Patient Preparation
Patient should be on a stable diet, ideally for two to three weeks prior to collection of blood. Fasting is not necessary for this profile, however fasting for 12 to 14 hours prior to collection of the specimen is recommended where the triglyceride value provides a priori diagnostic information such as screening for familial hypercholesterolemia or early onset heart disease, pancreatitis, or confirming hypertriglyceridemia.
Test Details
Use
This test is intended to help inform the clinician about the presence of hyperlipidemia as an index to cardiovascular disease and to identify patients with chronic kidney disease.
Limitations
LDL cholesterol cannot be calculated if triglyceride is >800 mg/dL.
Methodology
Lipid Profile With Non‐HDL Cholesterol: See individual tests.
Kidney Profile ‐ creatinine: kinetic jaffe. Albumin: immunoturbidimetric
Additional Information
The relationship between diabetes, cardiovascular disease, and chronic kidney disease is widely recognized. Among individuals with type 2 diabetes, cardiovascular disease is the leading cause of morbidity and mortality. Chronic kidney disease occurs in 20% to 40% of patients with diabetes and may be present at the time of diagnosis.
While not considered to be a clinical entity itself, individuals with prediabetes are at increased risk for diabetes and cardiovascular disease. Additionally, observational evidence has linked prediabetes with early nephropathy, chronic kidney disease, small fiber neuropathy, diabetic retinopathy, and increased risk of macrovascular disease.
References
American Diabetes Association. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2018.Diabetes Care. 2018 Jan; 41(Suppl 1):S86-S104.29222380
Eckel RH, Kahn R, Robertson RM, Rizza RA. Preventing cardiovascular disease and diabetes: a call to action from the American Diabetes Association and the American Heart Association. Circulation. 2006 Jun 27;113(25):2943-2946.16801475
Executive Summary of The Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. JAMA. 2001 May 16;285(19):2486-2497.11368702
Lamarche B, Tchernof A, Moorjani S, et al. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Québec Cardiovascular Study. Circulation. 1997 Jan 7;95(1):69-75.8994419
Ridker PM, Rifai N, Cook NR, Bradwin G, Buring JE. Non-HDL cholesterol, apolipoproteins A-1 and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. JAMA. 2005 Jul 20;294(3):326-333.16030277
LOINC® Map
| Order Code | Order Code Name | Order Loinc | Result Code | Result Code Name | UofM | Result LOINC |
|---|---|---|---|---|---|---|
| 023400 | Diabetes Comorbidity Risk | 001370 | Creatinine | mg/dL | 2160-0 | |
| 023400 | Diabetes Comorbidity Risk | 013672 | Creatinine, Urine | mg/dL | 2161-8 | |
| 023400 | Diabetes Comorbidity Risk | 140097 | Albumin, Urine | ug/mL | 14957-5 | |
| 023400 | Diabetes Comorbidity Risk | 140291 | Alb/Creat Ratio | mg/g creat | 9318-7 | |
| 023400 | Diabetes Comorbidity Risk | 001065 | Cholesterol, Total | mg/dL | 2093-3 | |
| 023400 | Diabetes Comorbidity Risk | 001172 | Triglycerides | mg/dL | 2571-8 | |
| 023400 | Diabetes Comorbidity Risk | 011817 | HDL Cholesterol | mg/dL | 2085-9 | |
| 023400 | Diabetes Comorbidity Risk | 011919 | VLDL Cholesterol Cal | mg/dL | 13458-5 | |
| 023400 | Diabetes Comorbidity Risk | 012059 | LDL Chol Calc (NIH) | mg/dL | 13457-7 | |
| 023400 | Diabetes Comorbidity Risk | 011923 | LDL Calc Comment: | N/A | ||
| 023400 | Diabetes Comorbidity Risk | 011976 | Non-HDL Cholesterol | mg/dL | 43396-1 | |
| 023400 | Diabetes Comorbidity Risk | 100779 | eGFR | mL/min/1.73 | 98979-8 |
© 2021 Laboratory Corporation of America® Holdings and Lexi-Comp Inc. All Rights Reserved.
CPT Statement/Profile Statement
The LOINC® codes are copyright © 1994-2021, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. Permission is granted in perpetuity, without payment of license fees or royalties, to use, copy, or distribute the LOINC® codes for any commercial or non-commercial purpose, subject to the terms under the license agreement found at https://loinc.org/license/. Additional information regarding LOINC® codes can be found at LOINC.org, including the LOINC Manual, which can be downloaded at LOINC.org/downloads/files/LOINCManual.pdf